TY - JOUR
T1 - Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation
T2 - a meta-analysis
AU - Li, Danyang
AU - Pain, Oliver
AU - Fabbri, Chiara
AU - Wong, Win Lee Edwin
AU - Lo, Chris Wai Hang
AU - Ripke, Stephan
AU - Cattaneo, Annamaria
AU - Souery, Daniel
AU - Dernovsek, Mojca Z
AU - Henigsberg, Neven
AU - Hauser, Joanna
AU - Lewis, Glyn
AU - Mors, Ole
AU - Perroud, Nader
AU - Rietschel, Marcella
AU - Uher, Rudolf
AU - Maier, Wolfgang
AU - Baune, Bernhard T
AU - Biernacka, Joanna M
AU - Bondolfi, Guido
AU - Kato, Masaki
AU - Domschke, Katharina
AU - Liu, Yu-Li
AU - Serretti, Alessandro
AU - Tsai, Shih-Jen
AU - Weinshilboum, Richard
AU - McIntosh, Andrew M
AU - Lewis, Cathryn M
AU - GSRD Consortium, the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium
N1 - © 2024. The Author(s).
PY - 2024/7/19
Y1 - 2024/7/19
N2 - Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual clinical and genetic data from 13 studies of European and East Asian ancestry populations were collected. The antidepressant response was clinically assessed as remission and percentage improvement. Imputed genotype was used to translate genetic polymorphisms to metabolic phenotypes (poor, intermediate, normal, and rapid+ultrarapid) of CYP2C19 and CYP2D6. CYP2D6 structural variants cannot be imputed from genotype data, limiting the determination of metabolic phenotypes, and precluding testing for association with response. The association of CYP2C19 metabolic phenotypes with treatment response was examined using normal metabolizers as the reference. Among 5843 depression patients, a higher remission rate was found in CYP2C19 poor metabolizers compared to normal metabolizers at nominal significance but did not survive after multiple testing correction (OR = 1.46, 95% CI [1.03, 2.06], p = 0.033, heterogeneity I
2 = 0%, subgroup difference p = 0.72). No metabolic phenotype was associated with percentage improvement from baseline. After stratifying by antidepressants primarily metabolized by CYP2C19, no association was found between metabolic phenotypes and antidepressant response. Metabolic phenotypes showed differences in frequency, but not effect, between European- and East Asian-ancestry studies. In conclusion, metabolic phenotypes imputed from genetic variants using genotype were not associated with antidepressant response. CYP2C19 poor metabolizers could potentially contribute to antidepressant efficacy with more evidence needed. Sequencing and targeted pharmacogenetic testing, alongside information on side effects, antidepressant dosage, depression measures, and diverse ancestry studies, would more fully capture the influence of metabolic phenotypes.
AB - Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual clinical and genetic data from 13 studies of European and East Asian ancestry populations were collected. The antidepressant response was clinically assessed as remission and percentage improvement. Imputed genotype was used to translate genetic polymorphisms to metabolic phenotypes (poor, intermediate, normal, and rapid+ultrarapid) of CYP2C19 and CYP2D6. CYP2D6 structural variants cannot be imputed from genotype data, limiting the determination of metabolic phenotypes, and precluding testing for association with response. The association of CYP2C19 metabolic phenotypes with treatment response was examined using normal metabolizers as the reference. Among 5843 depression patients, a higher remission rate was found in CYP2C19 poor metabolizers compared to normal metabolizers at nominal significance but did not survive after multiple testing correction (OR = 1.46, 95% CI [1.03, 2.06], p = 0.033, heterogeneity I
2 = 0%, subgroup difference p = 0.72). No metabolic phenotype was associated with percentage improvement from baseline. After stratifying by antidepressants primarily metabolized by CYP2C19, no association was found between metabolic phenotypes and antidepressant response. Metabolic phenotypes showed differences in frequency, but not effect, between European- and East Asian-ancestry studies. In conclusion, metabolic phenotypes imputed from genetic variants using genotype were not associated with antidepressant response. CYP2C19 poor metabolizers could potentially contribute to antidepressant efficacy with more evidence needed. Sequencing and targeted pharmacogenetic testing, alongside information on side effects, antidepressant dosage, depression measures, and diverse ancestry studies, would more fully capture the influence of metabolic phenotypes.
KW - Female
KW - Humans
KW - Male
KW - Antidepressive Agents/therapeutic use
KW - Asian People/genetics
KW - Cytochrome P-450 CYP2C19/genetics
KW - Cytochrome P-450 CYP2D6/genetics
KW - Depressive Disorder, Major/drug therapy
KW - Genotype
KW - Phenotype
KW - Treatment Outcome
KW - White People/genetics
UR - https://doi.org/10.1038/s41398-024-03064-x
U2 - 10.1038/s41398-024-02981-1
DO - 10.1038/s41398-024-02981-1
M3 - Article
C2 - 39025838
SN - 2158-3188
VL - 14
JO - Translational Psychiatry
JF - Translational Psychiatry
IS - 1
M1 - 296
ER -